FrancophonIA/ELRC3.0 huggingface dataset:
English: It is usually injected under the skin of the belly or upper arm immediately before a meal, although it may be given up to 20 minutes after starting a meal if necessary.
Maltese: Normalment dan jiġi injettat taħt il-ġilda taż-żaqq jew fil-parti ta' fuq tad-driegħ immedjatament qabel ikla, għalkemm jista' jingħata sa 20 minuta wara l-bidu ta' ikla, jekk ikun meħtieġ.
English: A third study involving 236 adults with type 2 diabetes and a starting HbA1c of around 7.9% found that adding mealtime Fiasp to treatment with a long-acting insulin and the diabetes medicine metformin improved blood glucose control.
Maltese: It-tielet studju li involva 236 pazjent bid-dijabete tat-tip 2 u b'HbA1c tal-bidu ta' madwar 7.9 % sab li ż-żieda tad-doża ta' Fiasp waqt il-ħin tal-ikel mal-kura b'insulina li taħdem fit-tul u l-mediċina taddijabete metformina tejbet il-kontroll tal-glukożju fid-demm.
English: In patients given Fiasp the HbA1c fell after 18 weeks by 1.16 percentage points, compared with 0.22 points in those on long-acting insulin and metformin alone.
Maltese: F'pazjenti li ngħataw Fiasp, it-tnaqqis fl-HbA1c wara 18-il ġimgħa kien ta' 1.16-il punt perċentwali, meta mqabbel ma' 0.22 punt perċentwali f'dawk li kienu fuq l-insulina li taħdem fit-tul u metformina biss.
English: This controls the level of blood glucose and reduces the symptoms and complications of diabetes.
Maltese: Din tikkontrolla l-livell ta' glukożju fid-demm u tnaqqas is-sintomi u l-komplikazzjonijiet tad-dijabete.
English: Both Fiasp and NovoRapid contain insulin aspart but Fiasp contains some different ingredients intended to help it to be absorbed rapidly.
Maltese: Aktar informazzjoni dwar Fiasp tinstab fis-sit web tal-Aġenzija:
English: For the full list of side effects and restrictions of Fiasp, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji u r-restrizzjonijiet ta' Fiasp, ara l-fuljett ta' tagħrif.
English: Fiasp is a medicine that is used to treat children from one year of age and adults with diabetes.
Maltese: Fiasp huwa mediċina li tintuża għall-kura ta' tfal mill-età ta' sena u adulti bid-dijabete.
English: The overall rate and severity of side effects was comparable with NovoRapid, although hypoglycaemia occurred more often in the first 2 hours after a dose of Fiasp.
Maltese: Ir-rata u s-severità globali tal-effetti sekondarji kienu komparabbli ma' NovoRapid, għalkemm l-ipogliċemija seħħet aktar ta' spiss fl-ewwel sagħtejn wara doża ta' Fiasp.
English: Hypoglycaemia can occur more quickly with Fiasp than with other mealtime insulins.
Maltese: Għaliex Fiasp ġie awtorizzat fl-UE?
English: The slightly higher risk of hypoglycaemia at night in children treated with Fiasp is addressed in the product information and is considered manageable.
Maltese: Ir-riskju kemxejn ogħla ta' ipogliċemija bil-lejl fit-tfal ikkurati bi Fiasp huwa indirizzat fl-informazzjoni dwar il-prodott u huwa kkunsidrat bħala maniġġabbli.
English: How is Fiasp used?
Maltese: Kif jintuża Fiasp?
English: The main measure of effectiveness was the medicine's ability to decrease the level in the blood of glycosylated haemoglobin (HbA1c), a substance which indicates how well blood glucose is controlled over time.
Maltese: Il-kejl ewlieni tal-effettività kien l-abbiltà tal-mediċina li tnaqqas il-livell ta' emoglobina glikosilata (HbA1c) fid-demm, sustanza li tindika kemm hu kkontrollat tajjeb il-glukożju fiddemm maż-żmien.
English: (See section 5.3).
Maltese: (Ara sezzjoni 5.3).
English: Aluminium/aluminium blisters (PA/PA/Al/PVC/Al).
Maltese: Folji tal-aluminju/aluminju (PA/PA/Al/PVC/Al).
English: Corticosteroïds (systemic route)
Maltese: Kortikosterojdi (rotta sistemika)
English: The active substance is telmisartan.
Maltese: Is-sustanza attiva hi telmisartan.
English: Date of last renewal: 11 December 2008
Maltese: Data tal-aħħar tiġdid: 11 ta' Diċembru, 2008
English: Pharmacotherapeutic group: Angiotensin II Antagonists, plain, ATC Code: C09CA07.
Maltese: Antagonisti ta' angiotensin II, sempliċi, Kodiċi ATC: C09CA07.
English: Pritor contains sorbitol.
Maltese: Pritor fih sorbitol.
English: Pharmacokinetic studies in patients with hepatic impairment showed an increase in absolute bioavailability up to nearly 100 %.
Maltese: Studji farmakokinetiċi f'pazjenti b'indeboliment epatiku juru żieda fil-biodisponibilità assoluta sa kważi 100%.
English: Telmisartan is largely bound to plasma protein (>99.5 %), mainly albumin and alpha-1 acid glycoprotein.
Maltese: Telmisartan fil-biċċa l-kbira tiegħu jeħel mal-proteina fil-plażma (>99.5 %), primarjament ma' lalbumina u alpha-1 acid glycoprotein.
English: The incidence of the primary endpoint was similar in the telmisartan (16.7 %) and ramipril (16.5 %) groups.
Maltese: L-inċidenza tar-riżultat aħħari primarju kienet simili fil-gruppi ta' telmisartan (16.7%) u ramipril (16.5%).
English: Kaiser-Wilhelm-Allee 51368 Leverkusen Germany
Maltese: Kaiser-Wilhelm-Allee 51368 Leverkusen
English: Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).
Maltese: Ir-reazzjonijiet avversi ġew ikklassifikati skond kategoriji ta' frekwenza bl-użu tal-konvenzjoni li ġejja: komuni ħafna (≥1/10); komuni (≥1/100 sa <1/10); mhux komuni (≥1/1,000 sa <1/100); rari (≥1/10,000 sa <1/1,000), rari ħafna (<1/10,000).
English: Telmisartan is characterised by biexponential decay pharmacokinetics with a terminal elimination half-life of >20 hours.
Maltese: Telmisartan hu kkaratterizzat minn farmakokinetiċi b'decay bi-esponenzjali, b'half-life ta' leliminazzjoni terminali ta' >20 siegħa.
English: 14 tablets 28 tablets 30 tablets 56 tablets 90 tablets 98 tablets 280 tablets 28 x 1 tablets
Maltese: 14-il pillola 28 pillola 30 pillola 56 pillola 90 pillola 98 pillola 280 pillola 28 x 1 pilloli
English: Possible side effects of Pritor
Maltese: Effetti sekondarji possibbli ta' Pritor
English: The mean absolute bioavailability for telmisartan is about 50 %.
Maltese: Il-medja talbiodisponibilità assoluta għal telmisartan hi ta' madwar 50%.
English: • Second and third trimesters of pregnancy (see sections 4.4 and 4.6)
Maltese: • It-tieni u t-tielet trimestru tat-tqala (ara sezzjonijiet 4.4 u 4.6)
English: Cumulative urinary excretion is <1 % of dose.
Maltese: L-eliminazzjoni kumulattiva fl-awrina hi ta' <1% taddoża.
English: Pritor 20 mg tablets Pack sizes: Blister with 14, 28, 30, 56, 90 or 98 tablets.
Maltese: Pritor 20 mg pilloli Daqsijiet tal-pakketti: Folja b'14, 28, 30, 56, 90 jew 98 pillola.
English: Manufacturer Bayer AG
Maltese: Manifattur Bayer AG
English: Telmisartan selectively binds the AT1 receptor.
Maltese: Telmisartan jeħel b'mod selettiv marriċettur AT1.
English: NN: {number} [national reimbursement number or other national number identifying the medicinal Product]
Maltese: {numru} [numru tar-rimborż nazzjonali jew numru nazzjonali tal-identifikazzjoni ieħor għallprodott mediċinali]
English: • type 2 diabetes mellitus with documented target organ damage
Maltese: • dijabete mellitus ta' tip 2 bi ħsara dokumentata tal-organu fil-mira
English: Do not take Pritor
Maltese: Tiħux Pritor
English: Contains sorbitol (E420).
Maltese: TA' EĊĊIPJENTI Fih sorbitol (E420).
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 11 December 1998
Maltese: DATA TAL-EWWEL AWTORIZZAZZJONI/TIĠDID TAL-AWTORIZZAZZJONI Data tal-ewwel awtorizzazzjoni: 11 ta' Diċembru, 1998
English: The antihypertensive efficacy of telmisartan is comparable to that of agents representative of other classes of antihypertensive medicinal products (demonstrated in clinical trials comparing telmisartan to amlodipine, atenolol, enalapril, hydrochlorothiazide, and lisinopril).
Maltese: L-effikaċja anti-ipertensiva ta' telmisartan hi komparabbli ma' dik ta' mediċini li jirrappreżentaw kategoriji oħrajn ta' prodotti mediċinali anti-ipertensivi (dan intwera fi provi kliniċi li qabblu telmisartan ma' amlodipine, atenolol, enalapril, hydrochlorothiazide, u lisinopril).
English: ONTARGET (ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) compared the effects of telmisartan, ramipril and the combination of telmisartan and ramipril on cardiovascular outcomes in 25620 patients aged 55 years or older with a history of coronary artery disease, stroke, TIA, peripheral arterial disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage (e.g. retinopathy, left ventricular hypertrophy, macro- or microalbuminuria), which is a population at risk for cardiovascular events.
Maltese: ONTARGET (ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) qabbel l-effetti ta' telmisartan, ramipril u t-taħlita ta' telmisartan u ramipril fuq riżultati kardjovaskulari f'25620 pazjent li kellhom 55 sena jew aktar, ma' storja medika ta' mard arterjali koronarju, puplesija, TIA, mard arterjali periferali, jew dijabete mellitus ta' tip 2 akkompanjat minn evidenza ta' ħsara fl-organi fil-mira (eż. retinopatija, ipertrofija ventrikulari tax-xellug, makro- jew mikroalbuminurija), li hi popolazzjoni f'riskju għal avvenimenti kardjovaskulari.
English: m. b. H. Tel: +43-(0)1-711 46-0
Maltese: Bayer Austria Ges. m. b. H. Tel: +43-(0)1-711 46-0
English: : for further descriptions, please see sub-section “Description of selected adverse reactions” Description of selected adverse reactions
Maltese: : għal deskrizzjonijiet addizzjonali, jekk jogħġbok ara sottosezzjoni “Deskrizzjoni ta' reazzjonijiet avversi magħżula”
English: INFORMATION IN BRAILLE Pritor 40 mg
Maltese: INFORMAZZJONI BIL-BRAILLE Pritor 40 mg
English: • Lithium containing medicines to treat some types of depression.
Maltese: • Mediċini li fihom il-lithium għall-kura ta' xi tipi ta' dipressjoni.
English: The other ingredients are povidone, meglumine, sodium hydroxide, sorbitol (E420) and magnesium stearate.
Maltese: Is-sustanzi l-oħra huma povidone, meglumine, sodium hydroxide, sorbitol (E420) u magnesium stearate.
English: There was no evidence for benefit on cardiovascular mortality (hazard ratio 1.03, 95 % CI 0.85 - 1.24).
Maltese: Ma kien hemm l-ebda evidenza ta' benefiċċju fuq mortalità kardjovaskulari (proporzjon ta' periklu ta' 1.03, 95% CI 0.85 - 1.24).
English: INFORMATION IN BRAILLE Pritor 20 mg
Maltese: INFORMAZZJONI BIL-BRAILLE Pritor 20 mg
English: Anaphylactic reaction, hypersensitivity Metabolism and nutrition disorders Uncommon: Rare:
Maltese: Reazzjoni anafilattika, sensittività eċċessiva Disturbi fil-metaboliżmu u n-nutrizzjoni Mhux komuni:
English: Telmisartan is metabolised by conjugation to the glucuronide of the parent compound.
Maltese: Telmisartan hu metabolat permezz ta' konjugazzjoni għal glucuronide tal-kompost prinċipali.
English: Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.
Maltese: Żewġ provi kbar ikkontrollati li fihom il-parteċipanti ntgħażlu b'mod każwali, (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) u VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) eżaminaw l-użu tal-kombinazzjoni ta' inibitur ta' ACE ma' imblokkaturi tar-riċetturi ta' angiotensin II.
English: INFORMATION IN BRAILLE Pritor 80 mg
Maltese: INFORMAZZJONI BIL-BRAILLE Pritor 80 mg
English: Tlf: +45-45 23 50 00
Maltese: Bayer A/S Tlf: +45-45 23 50 00
English: One blister contains 7 or 10 tablets.
Maltese: Folja waħda fiha 7 jew 10 pilloli.
English: After adjustment for age group effects mean SBP changes from baseline (primary objective) were -14.5 (1.7) mm Hg in the telmisartan 2 mg/kg group, -9.7 (1.7) mm Hg in the telmisartan 1 mg/kg group, and -6.0 (2.4) in the placebo group.
Maltese: Wara aġġustament għalleffetti tal-grupp ta' età, il-medja ta' tibdil tal-SBP mil-linja bażi (oġġettiv primarju) kienet ta'14.5 (1.7) mm Hg fil-grupp ta' telmisartan 2 mg/kg, -9.7 (1.7) mm Hg fil-grupp ta' telmisartan 1 mg/kg, u -6.0
English: In the "Prevention Regimen For Effectively avoiding Second Strokes" (PRoFESS) trial in patients 50 years and older, who recently experienced stroke, an increased incidence of sepsis was noted for telmisartan compared with placebo, 0.70 % vs. 0.49 % [RR 1.43 (95 % confidence interval 1.002.06)]; the incidence of fatal sepsis cases was increased for patients taking telmisartan (0.33 %) vs. patients taking placebo (0.16 %) [RR 2.07 (95 % confidence interval 1.14 - 3.76)].
Maltese: Fil-prova "Kors ta' Prevenzjoni Biex Tevita b'Mod Effettiv Puplesiji Oħrajn" (Prevention Regimen For Effectively avoiding Second Strokes - PRoFESS), f'pazjenti li għandhom 50 sena jew aktar, li dan l-aħħar kellhom puplesija, kienet osservata żieda fl-inċidenza ta' sepsis għal telmisartan meta mqabbel mal-plaċebo, 0.70 % vs. 0.49 % [RR 1.43 (95% intervall ta' kunfidenza 1.00 - 2.06)]; l-inċidenza ta' każijiet ta' sepsis fatali żdiedet għal pazjenti li kienu qed jieħdu telmisartan (0.33 %) vs. pazjenti li kienu qed jieħdu l-plaċebo (0.16 %) [RR 2.07 (95% intervall ta' kunfidenza 1.14 - 3.76)].
English: • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
Maltese: • Sensittività eċċessiva għas-sustanza attiva jew għal kwalunkwe sustanza mhux attiva elenkata fis-sezzjoni 6.1
English: Each 40 mg tablet contains 169 mg sorbitol (E420).
Maltese: Kull pillola ta' 40 mg fiha 169 mg ta' sorbitol (E420).
English: Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).
Maltese: Dejta mill-provi kliniċi wriet li imblokk doppju tas-sistema renin-angiotensin-aldosterone (RAAS) permezz tal-użu kombinat ta' inibituri ta' ACE, imblokkaturi tar-riċetturi ta' angiotensin II jew aliskiren hu assoċjat ma' frekwenza ogħla ta' avvenimenti avversi bħal pressjoni baxxa, iperkalemija u tnaqqis fil-funzjoni tal-kliewi (li tinkludi insuffiċjenza akuta tal-kliewi) meta mqabbla mal-użu ta' mediċina waħda li taġixxi fuq RAAS (ara sezzjonijiet 4.3, 4.4 u 5.1).
English: Each 80 mg tablet contains 338 mg sorbitol (E420).
Maltese: Kull pillola ta' 80 mg fiha 338 mg ta' sorbitol (E420).
English: MON TUE WED THU FRI SAT SUN
Maltese: Sewqan u tħaddim ta' magni
English: Pritor 40 mg tablets
Maltese: Pritor 40 mg pilloli
English: Back pain (e.g. sciatica), muscle spasms, myalgia, Arthralgia, pain in extremity, tendon pain (tendinitis like symptoms)
Maltese: Uġigħ fid-dahar (eż. xjatika), spażmi tal-muskoli, mijalġja Artralġja, uġigħ fl-estremitajiet, uġigħ fit-tendini (sintomi qishom tendinite)
English: Currently available data are described in section 5.1 and 5.2 but no recommendation on a posology can be made.
Maltese: Data disponibbli hija deskritta fis-sezzjonijiet 5.1 u 5.2 iżda ma tista' ssir l-ebda rakkomandazzjoni dwar pożoloġija.
English: Whilst there is no controlled epidemiological data on the risk with angiotensin II receptor antagonists, similar risks may exist for this class of drugs.
Maltese: Filwaqt li m'hemm l-ebda dejta epidemjoloġika kkontrollata fuq ir-riskju b'antagonisti tarriċetturi ta' angiotensin II, riskji simili jistgħu jkunu jeżistu għal din il-klassi ta' mediċini.
English: See also information under the heading “Do not take Pritor”.
Maltese: Ara wkoll l-informazzjoni taħt t-titlu “Tiħux Pritor”.
English: Infections and infestations Uncommon:
Maltese: Infezzjonijiet u infestazzjonijiet Mhux komuni:
English: Bradycardia Tachycardia
Maltese: Bradikardija
English: Telmisartan is an orally active and specific angiotensin II receptor (type AT1) antagonist.
Maltese: Telmisartan hu antagonist tar-riċettur ta' angiotensin II (tip AT1) li hu effettiv u speċifiku, u hu oralment attiv.
English: ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.
Maltese: ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) kien studju maħsub biex jittestja l-benefiċċju taż-żieda ta' aliskiren ma' terapija standard ta' inibitur ta' ACE jew imblokkatur tar-riċetturi ta' angiotensin II f'pazjenti b'dijabete mellitus ta' tip 2 u mard kroniku tal-kliewi, mard kardjovaskulari, jew it-tnejn.
English: Pritor is available in blister packs containing 14, 28, 30, 56, 90 or 98 tablets.
Maltese: Pritor hu disponibbli f'pakketti b'folji ta' 14, 28, 30, 56, 90 jew 98 pillola.
English: Telmisartan was found to be similarly effective to ramipril in the pre-specified secondary endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke [0.99 (97.5 % CI 0.901.08), p (non-inferiority) = 0.0004], the primary endpoint in the reference study HOPE (The Heart Outcomes Prevention Evaluation Study), which had investigated the effect of ramipril vs. placebo.
Maltese: Instab li telmisartan kien effettiv bl-istess mod bħal ramipril fir-riżultat aħħari sekondarju speċifikat minn qabel ta' mewt kardjovaskulari, infart mijokardijaku mhux fatali, u puplesija mhux fatali [0.99 (97.5% CI 0.90 - 1.08), p (non-inferjorità) = 0.0004], ir-riżultat aħħari primarju fl-istudju ta' referenza
English: The adjusted DBP changes from baseline were -8.4 (1.5) mm Hg, -4.5 (1.6) mm Hg and -3.5 (2.1) mm Hg respectively.
Maltese: Hg u -3.5 (2.1) mm Hg rispettivament.
English: When telmisartan is taken with food, the reduction in the area under the plasma concentration-time curve (AUC0-∞) of telmisartan varies from approximately 6 % (40 mg dose) to approximately 19 % (160 mg dose).
Maltese: Meta telmisartan jittieħed ma' l-ikel, ittnaqqis taż-żona taħt il-kurva tal-konċentrazzjoni tal-plażma-żmien (AUC0-∞) ta' telmisartan tvarja minn madwar 6% (doża ta' 40 mg) sa madwar 19% (doża ta' 160 mg).
English: Pritor 40 mg and 80 mg tablets 4 years
Maltese: Pritor 40 mg u 80 mg pilloli 4 snin
English: Pack sizes: Blister with 14, 28, 30, 56, 90, 98 or 280 tablets or perforated unit dose blisters with 28 x 1 tablets.
Maltese: Folja b'14, 28, 30, 56, 90, 98 jew 280 pillola jew folji perforati b'doża waħda bi 28 x 1 pillola.
English: Renal impairment including acute renal failure General disorders and administration site conditions Uncommon: Rare:
Maltese: Indeboliment renali li jinkludi insuffiċjenza renali akuta Disturbi ġenerali u kondizzjonijiet ta' mnejn jingħata Mhux komuni: Rari:
English: Pritor 80 mg tablets
Maltese: Pritor 80 mg pilloli
English: Pritor is available in blister packs containing 14, 28, 30, 56, 90, 98 or 280 tablets, or unit dose blister packs containing 28 x 1 tablets.
Maltese: Pritor hu disponibbli f'pakketti b'folji ta' 14, 28, 30, 56, 90, 98 jew 280 pillola jew pakketti bil-folji bid-doża tal-unità li fihom 28 x 1 pilloli.
English: Studies in animals have shown reproductive toxicity (see section 5.3).
Maltese: Studji f'annimali wrew effett tossiku fuq is-sistema riproduttiva (ara sezzjoni 5.3).
English: Pritor 20 mg tablets
Maltese: Pritor 20 mg pilloli
English: Each 20 mg tablet contains 84 mg sorbitol (E420).
Maltese: Kull pillola ta' 20 mg fiha 84 mg ta' sorbitol (E420).
English: Pritor 40 mg and 80 mg tablets
Maltese: Pritor 40 mg u 80 mg pilloli
English: Telmisartan does not exhibit any partial agonist activity at the AT1 receptor.
Maltese: Telmisartan ma jesibixxi l-ebda attività agonista parzjali għar-riċettur AT1.
English: In human, an 80 mg dose of telmisartan almost completely inhibits the angiotensin II evoked blood pressure increase.
Maltese: Fil-bniedem, doża ta' 80 mg ta' telmisartan kważi tinibixxi kompletament iż-żieda fil-pressjoni taddemm ikkawżata minn angiotensin II.
English: Other medicines and Pritor
Maltese: Mediċini oħra u Pritor
English: • Renal artery stenosis (narrowing of the blood vessels to one or both kidneys).
Maltese: • Stenosi tal-arterji renali (tidjiq tal-vini/arterji lejn kilwa waħda jew lejn iż-żewġ kliewi).
English: The use of medicinal products that affect the renin-angiotensin-aldosterone system may cause hyperkalaemia.
Maltese: L-użu ta' prodotti mediċinali li jaffettwaw is-sistema renin-angiotensin-aldosterone, jista' jikkawża liperkalemija.
English: Pritor 20 mg tablets 3 years
Maltese: Pritor 20 mg pilloli 3 snin
English: The concomitant use of Pritor with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m2) (see sections 4.5, and 5.1).
Maltese: L-użu fl-istess ħin ta' Pritor flimkien ma' prodotti li fihom aliskiren huwa kontraindikat f'pazjenti b'dijabete mellitus jew b'indeboliment tal-kliewi (GFR < 60 ml/min/1.73 m2) (ara sezzjonijiet 4.5 u
English: • Medicines that may increase blood potassium levels such as salt substitutes containing potassium, potassium-sparing diuretics (certain 'water tablets'), ACE inhibitors, angiotensin II receptor antagonists, NSAIDs (non steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen), heparin, immunosuppressives (e.g. cyclosporin or tacrolimus), and the antibiotic trimethoprim.
Maltese: • Mediċini li jistgħu jżidu il-livelli tal-potassium fid-demm bħal sostituti tal-melħ li fihom ilpotassium, dijuretiċi li ma jneħħux potassium (ċerti ‘pilloli tal-awrina'), inibituri ACE, antagonisti tar-riċettur ta' angiotensin II, NSAIDs (mediċini mhux sterojdi kontra linfjammazzjoni, eż. aspirina jew ibuprofen), eparina, immunosoppressivi (eż. cyclosporin jew tacrolimus), u l-antibijotiku trimethoprim.
English: EU/1/98/089/011 (14 tablets) EU/1/98/089/012 (28 tablets) EU/1/98/089/020 (30 tablets) EU/1/98/089/013 (56 tablets) EU/1/98/089/019 (90 tablets) EU/1/98/089/014 (98 tablets)
Maltese: EU/1/98/089/011 (14-il pillola) EU/1/98/089/012 (28 pillola) EU/1/98/089/020 (30 pillola) EU/1/98/089/013 (56 pillola) EU/1/98/089/019 (90 pillola) EU/1/98/089/014 (98 pillola)
English: Pritor 40 mg tablets White oblong tablets of 3.8 mm engraved with the code number '51H' on one side.
Maltese: Pilloli bojod ta' 3.8 mm b'forma oblunga li fuqhom hemm imnaqqax in-numru tal-kodiċi ‘51H' fuq naħa waħda.
English: Pritor is contraindicated in patients with severe hepatic impairment (see section 4.3).
Maltese: Pritor hu kontraindikat f'pazjenti b'indeboliment serju tal-fwied (ara sezzjoni 4.3).
English: Potassium sparing diuretics e.g. spirinolactone, eplerenone, triamterene, or amiloride, potassium supplements, or potassium-containing salt substitutes may lead to a significant increase in serum potassium.
Maltese: Dijuretiċi li ma jneħħux potassium, eż. spirinolactone, eplerenone, triamterene, jew amiloride, supplimenti tal-potassium, jew sostituti tal-melħ li fihom il-potassium jistgħu jwasslu għal żieda sinifikanti fil-potassium fis-serum.
English: NAME OF THE MARKETING AUTHORISATION HOLDER Bayer (Logo)
Maltese: FIS-SUQ Bayer (Logo)
English: Patients with rare hereditary problems of fructose intolerance should not take Pritor.
Maltese: Pazjenti li għandhom problemi ereditarji rari ta' intolleranza għall-fructose m'għandhomx jieħdu Pritor.
English: Prior treatment with high dose diuretics such as furosemide (loop diuretic) and hydrochlorothiazide (thiazide diuretic) may result in volume depletion and in a risk of hypotension when initiating therapy with telmisartan.
Maltese: Il-kura fil-passat b'dożi qawwija ta' dijuretiċi bħal furosemide (dijuretiku loop) u hydrochlorothiazide (dijuretiku thiazide) tista' tirriżulta fi tnaqqis tal-volum u f'riskju ta' pressjoni tad-demm baxxa ħafna meta tibda t-terapija b'telmisartan.
English: The elimination half-life is not changed in patients with hepatic impairment.
Maltese: Il-half-life ta' l-eliminazzjoni ma tinbidilx f'pazjenti b'indeboliment epatiku.